Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1529
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Targretin (Capsule)
|
| dailymed-instance:dosage |
The recommended initial dose of Targretin
capsules is 300 mg/m/day. (See Table 4.)
Targretin capsules should be taken as a single
oral daily dose with a meal. See CONTRAINDICATIONS:
Pregnancy: Category X section for precautions to prevent
pregnancy and birth defects in women of child-bearing potential. Dose Modification Guidelines: The 300 mg/m/day dose
level of Targretin capsules may be adjusted to 200
mg/m/day then to 100 mg/m/day, or
temporarily suspended, if necessitated by toxicity. When toxicity is
controlled, doses may be carefully readjusted upward. If there is no
tumor response after eight weeks of treatment and if the initial dose of
300 mg/m/day is well tolerated, the dose may be escalated to
400 mg/m/day with careful monitoring. Duration of Therapy: In clinical trials in CTCL,
Targretin capsules were administered for up to
97 weeks. Targretin capsules should be continued as
long as the patient is deriving benefit.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:genericDr... | |
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:genericMe... |
bexarotene
|
| dailymed-instance:fullName |
Targretin (Capsule)
|
| dailymed-instance:indicatio... |
Targretin (bexarotene) capsules are
indicated for the treatment of cutaneous manifestations of cutaneous
T-cell lymphoma in patients who are refractory to at least one prior
systemic therapy.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Targretin
|